Erik K Henricson
Overview
Explore the profile of Erik K Henricson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramli A, Liu X, Berndt K, Chuah C, Goude E, Kaethler L, et al.
Sensors (Basel)
. 2024 Feb;
24(4).
PMID: 38400313
Estimation of temporospatial clinical features of gait (CFs), such as step count and length, step duration, step frequency, gait speed, and distance traveled, is an important component of community-based mobility...
2.
Ramli A, Liu X, Berndt K, Goude E, Hou J, Kaethler L, et al.
Sensors (Basel)
. 2024 Feb;
24(4).
PMID: 38400281
Differences in gait patterns of children with Duchenne muscular dystrophy (DMD) and typically developing (TD) peers are visible to the eye, but quantifications of those differences outside of the gait...
3.
Mercuri E, Osorio A, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al.
J Neurol
. 2023 Jul;
270(9):4583.
PMID: 37460854
No abstract available.
4.
Mercuri E, Osorio A, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al.
J Neurol
. 2023 Apr;
270(8):3896-3913.
PMID: 37115359
Objective: Strategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing, international, multicenter registry of real-world ataluren use in individuals with nonsense mutation Duchenne muscular dystrophy (nmDMD)...
5.
McDonald C, Mayer O, Hor K, Miller D, Goemans N, Henricson E, et al.
J Neuromuscul Dis
. 2022 Dec;
10(1):67-79.
PMID: 36565131
Background: Evidence on the long-term efficacy of steroids in Duchenne muscular dystrophy (DMD) after loss of ambulation is limited. Objective: Characterize and compare disease progression by steroid treatment (prednisone, deflazacort,...
6.
Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, et al.
Muscle Nerve
. 2022 Jun;
66(3):262-269.
PMID: 35715998
Introduction/aims: Pulmonary decline is a major issue in patients with Duchenne muscular dystrophy (DMD). Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations. Previous...
7.
Batra A, Barnard A, Lott D, Willcocks R, Forbes S, Chakraborty S, et al.
BMC Cardiovasc Disord
. 2022 Jun;
22(1):260.
PMID: 35681116
Background: The lack of dystrophin in cardiomyocytes in Duchenne muscular dystrophy (DMD) is associated with progressive decline in cardiac function eventually leading to death by 20-40 years of age. The...
8.
Guglieri M, Bushby K, McDermott M, Hart K, Tawil R, Martens W, et al.
JAMA
. 2022 Apr;
327(15):1456-1468.
PMID: 35381069
Importance: Corticosteroids improve strength and function in boys with Duchenne muscular dystrophy. However, there is uncertainty regarding the optimum regimen and dosage. Objective: To compare efficacy and adverse effects of...
9.
McDonald C, Marban E, Hendrix S, Hogan N, Ruckdeschel Smith R, Eagle M, et al.
Lancet
. 2022 Mar;
399(10329):1049-1058.
PMID: 35279258
Background: Cardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety and efficacy of sequential intravenous infusions of...
10.
McDonald C, Ramirez-Sanchez I, Oskarsson B, Joyce N, Aguilar C, Nicorici A, et al.
Muscle Nerve
. 2020 Oct;
63(2):239-249.
PMID: 33125736
Introduction: We conducted an open-label study to examine the effects of the flavonoid (-)-epicatechin in seven ambulatory adult patients with Becker muscular dystrophy (BMD). Methods: Seven participants received (-)-epicatechin 50 ...